This month marks the start of a new era for GlaxoSmithKline, with Emma Walmsley taking over from Sir Andrew Witty – and big pharma's first female CEO has said she is prepared to make tough ...

(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley ... In an early gaffe that ...

It’s been two and a half years since Emma Walmsley took over as CEO of GlaxoSmithKline, and at the time was seen as the protégé of her predecessor Sir Andrew Witty. Coming from the consumer ...

Walmsley, the only woman CEO of a major pharma company, told Fortune at the time that GSK was working on building its vaccine portfolio. That’s not the only avenue where GSK is growing.

CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S ...

GlaxoSmithkline chief executive Emma Walmsley was made a dame for services ... was made a Knight Bachelor for services to business, science, technology and to UK and Australia relations.

It’s been a big year for Emma Walmsley (pictured above), chief executive of Britain’s biggest drugmaker GSK. She was nominated to the board of tech giant Microsoft. She was named as one of the most ...

Five years into her transformation-focused tenure, Walmsley says the global drugmaker is at last ready to deliver results. She completed the final step of that overhaul this summer, spinning off ...